Trial Profile
Use of Response-Adapted Hypofractionated Radiation Therapy to Potentiate the Systemic Immune Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Apr 2023 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 31 Dec 2019 to 30 Jun 2023.
- 06 Apr 2021 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2022.